Profile data is unavailable for this security.
About the company
NanoViricides, Inc. is a development stage company, which is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Its lead drug candidate is NV-CoV-2 (API NV-387) for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. Its other advanced candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 is its nanoviricide drug candidate for COVID-19 containing the nanoviricide API, NV-387. NV-CoV-2-R is its other drug candidate for COVID-19, which is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates, NV-CoV-2 and NV-CoV-2-R independently. It is also developing drugs against a number of viral diseases, including RSV, oral and genital Herpes, viral diseases of the eye, including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu and others.
- Revenue in USD (TTM)0.00
- Net income in USD-9.51m
- Incorporated2005
- Employees7.00
- LocationNanoViricides Inc1 Controls DriveSHELTON 06484United StatesUSA
- Phone+1 (203) 937-6137
- Fax+1 (203) 859-5095
- Websitehttp://www.nanoviricides.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Singular Genomics Systems Inc | 2.49m | -96.21m | 27.02m | 255.00 | -- | 0.1724 | -- | 10.85 | -1.31 | -1.31 | 0.034 | 2.12 | 0.0091 | 0.233 | 32.98 | 9,764.71 | -35.33 | -- | -37.29 | -- | -41.49 | -- | -3,863.90 | -- | 9.54 | -- | 0.0614 | -- | 280.52 | -- | -4.34 | -- | -- | -- |
| Alterola Biotech Inc | 0.00 | -2.88m | 27.17m | 1.00 | -- | -- | -- | -- | -0.0027 | -0.0027 | 0.00 | -0.001 | 0.00 | -- | -- | 0.00 | -47.24 | -- | -63.88 | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -- | -- | 73.07 | -- | -- | -- |
| Aptorum Group Ltd | 431.38k | -2.82m | 27.25m | 3.00 | -- | 1.04 | -- | 63.16 | -0.9126 | -0.9126 | 0.0954 | 4.80 | 0.0208 | 30.36 | 3.88 | 143,793.30 | -20.92 | -40.45 | -19.62 | -42.36 | 2.45 | -4.04 | -1,006.30 | -1,233.68 | 1.18 | -- | 0.1694 | -- | -66.71 | 2.38 | 71.18 | -- | -78.15 | -- |
| Oncternal Therapeutics Inc | 1.15m | -36.38m | 27.26m | 27.00 | -- | 1.19 | -- | 23.68 | -12.35 | -12.35 | 0.3907 | 7.75 | 0.0263 | -- | -- | 42,629.63 | -83.23 | -49.40 | -95.97 | -54.51 | -- | -- | -3,160.73 | -1,342.98 | -- | -- | 0.00 | -- | -47.32 | -- | 10.62 | -- | -- | -- |
| Viracta Therapeutics Inc | 0.00 | -47.99m | 27.49m | 40.00 | -- | 4.88 | -- | -- | -1.24 | -1.24 | 0.00 | 0.2821 | 0.00 | -- | -- | 0.00 | -75.51 | -86.35 | -112.64 | -106.38 | -- | -- | -- | -11,853.94 | -- | -84.18 | 0.6277 | -- | -- | -- | -3.78 | -- | -- | -- |
| RenovoRx Inc | 0.00 | -8.05m | 27.78m | 8.00 | -- | 11.07 | -- | -- | -0.7249 | -0.7249 | 0.00 | 0.1048 | 0.00 | -- | -- | 0.00 | -172.23 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.47 | -- | -- | -- |
| BioVie Inc | 0.00 | -37.18m | 27.79m | 18.00 | -- | 1.47 | -- | -- | -0.9626 | -0.9626 | 0.00 | 0.3104 | 0.00 | -- | -- | 0.00 | -94.32 | -456.35 | -149.75 | -1,810.88 | -- | -- | -- | -- | -- | -- | 0.2969 | -- | -- | -- | -92.67 | -- | -- | -- |
| Biomx Inc | 0.00 | -37.14m | 27.92m | 58.00 | -- | -- | -- | -- | -0.6234 | -0.6234 | 0.00 | 0.3813 | 0.00 | -- | -- | 0.00 | -60.38 | -- | -72.74 | -- | -- | -- | -- | -- | -- | -2.25 | 0.00 | -- | -- | -- | 7.59 | -- | -- | -- |
| bioAffinity Technologies Inc | 4.94m | -8.37m | 27.98m | 75.00 | -- | 5.12 | -- | 5.67 | -0.9197 | -0.9197 | 0.5416 | 0.4687 | 0.5334 | 318.22 | 8.70 | 65,839.60 | -90.38 | -- | -104.93 | -- | 32.88 | -- | -169.42 | -- | 2.21 | -- | 0.1782 | -- | 52,660.42 | -- | 2.66 | -- | -- | -- |
| NanoViricides Inc | 0.00 | -9.51m | 28.35m | 7.00 | -- | 2.66 | -- | -- | -0.8115 | -0.8115 | 0.00 | 0.9017 | 0.00 | -- | -- | 0.00 | -63.30 | -43.54 | -65.85 | -46.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.94 | -- | -8.90 | -- |
| Qilian International Holding Group Ltd | 46.47m | -7.78m | 28.60m | 298.00 | -- | 0.6684 | -- | 0.6154 | -0.2176 | -0.2176 | 1.30 | 1.20 | 0.8027 | 6.45 | 33.30 | 155,944.60 | -14.03 | 2.71 | -16.84 | 3.86 | 3.77 | 11.66 | -17.48 | 2.72 | 4.43 | -0.4812 | 0.0107 | 26.11 | -28.35 | -1.60 | -822.64 | -- | 12.86 | -- |
| Bolt Biotherapeutics Inc | 11.32m | -63.03m | 28.85m | 100.00 | -- | 0.277 | -- | 2.55 | -1.66 | -1.66 | 0.2987 | 2.73 | 0.0649 | -- | -- | 113,240.00 | -36.11 | -48.32 | -39.88 | -54.03 | -- | -- | -556.59 | -2,267.00 | -- | -- | 0.00 | -- | 37.48 | -- | 21.45 | -- | -6.61 | -- |
| Palatin Technologies, Inc. | 5.90m | -32.20m | 29.05m | 34.00 | -- | 18.40 | -- | 4.92 | -2.39 | -2.39 | 0.4275 | 0.0979 | 0.3189 | 0.6402 | 6.95 | 173,588.80 | -173.98 | -26.11 | -387.23 | -30.68 | 96.58 | -- | -545.58 | -126.20 | 1.20 | -- | 0.0443 | -- | 230.53 | -40.87 | 23.91 | -- | 80.82 | -- |
| Spruce Biosciences Inc | 10.13m | -46.75m | 30.50m | 22.00 | -- | 0.4578 | -- | 3.01 | -1.15 | -1.15 | 0.2483 | 1.62 | 0.0894 | -- | -- | 349,206.90 | -41.26 | -41.24 | -50.47 | -46.49 | -- | -- | -461.67 | -1,774.39 | -- | -114.54 | 0.0423 | -- | -- | -- | -3.77 | -- | -- | -- |
| Raphael Pharmaceutical Inc | 0.00 | -1.57m | 30.60m | 0.00 | -- | -- | -- | -- | -0.0929 | -0.0929 | 0.00 | -0.0055 | 0.00 | -- | -- | -- | -624.25 | -- | -- | -- | -- | -- | -- | -- | -- | -173.44 | -- | -- | -- | -- | 61.76 | -- | -- | -- |
Data as of May 31 2024. Currency figures normalised to NanoViricides Inc's reporting currency: US Dollar USD
9.68%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 454.70k | 3.86% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 158.75k | 1.35% |
| Banque Lombard Odier & Cie SA (Investment Management)as of 31 Mar 2024 | 150.00k | 1.27% |
| Geode Capital Management LLCas of 31 Mar 2024 | 109.49k | 0.93% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 84.50k | 0.72% |
| Bridgeway Capital Management LLCas of 31 Mar 2024 | 59.04k | 0.50% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 41.91k | 0.36% |
| City National Rochdale LLCas of 31 Mar 2024 | 30.54k | 0.26% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 29.55k | 0.25% |
| Citadel Securities LLCas of 31 Mar 2024 | 21.49k | 0.18% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
